2019-02-12
|
Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T Cell Response Against Immunosuppressive Tumors
published
| article-journal
doi:10.1158/1078-0432.ccr-18-3016
|
2016
|
Transcriptional profiling of macrophage and tumor cell interactions in vitro
published
| article-journal
| CC-BY-NC-ND
doi:10.1016/j.gdata.2016.02.009
|
2019-03-29
|
Clever-1 contributes to lymphocyte entry into the spleen via the red pulp
published
| article-journal
doi:10.1126/sciimmunol.aat0297
|
2020-11-13
|
Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors
unknown status
| post
doi:10.1101/2020.11.11.20227777
|
2021-03-27
|
A Distinct Cytokine Profile and Stromal Vascular Fraction Metabolic Status without Significant Changes in the Lipid Composition Characterizes Lipedema
published
| article-journal
doi:10.17863/cam.66411
|
2021-03-24
|
A Distinct Cytokine Profile and Stromal Vascular Fraction Metabolic Status without Significant Changes in the Lipid Composition Characterizes Lipedema
published
| article-journal
| CC-BY
doi:10.3390/ijms22073313
|
2022-11-28
|
Biallelic STAB1 pathogenic variants cause hereditary hyperferritinemia
unknown status
| post
doi:10.1101/2022.11.24.22282670
|
2021-06-02
|
Systemic blockade of Clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: Results from a phase I/II clinical trial
published
| article-journal
doi:10.1158/1078-0432.ccr-20-4862
|
2022-05-02
|
Nonclinical characterization of bexmarilimab, a Clever-1-targeting antibody for supporting immune defense against cancers
published
| article-journal
doi:10.1158/1535-7163.mct-21-0840
|
2023-11-14
|
Dimeric IgA specifically disables intracellular mutated oncodrivers
published
| article-journal
doi:10.1016/j.immuni.2023.10.014
|
2024-01-03
|
Table S2 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935436
|
2024-01-03
|
Data from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.c.7005684.v1
|
2024-01-03
|
Table S1 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935439.v1
|
2024-01-03
|
Figure S3 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935454
|
2024-01-03
|
Figure S1 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935460
|
2024-01-03
|
Figure S5 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935448.v1
|
2024-01-03
|
Figure S1 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935460.v1
|
2024-01-03
|
Figure S7 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935442.v1
|
2024-01-03
|
Figure S4 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935451
|
2024-01-03
|
Table S1 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935439
|
2024-01-03
|
Table S2 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935436.v1
|
2024-01-03
|
Figure S6 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935445.v1
|
2024-01-03
|
Figure S2 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935457.v1
|
2024-01-03
|
Figure S3 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935454.v1
|
2024-01-03
|
Figure S7 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935442
|
2024-01-03
|
Figure S2 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935457
|
2024-01-03
|
Figure S6 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935445
|
2024-01-03
|
Data from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.c.7005684
|
2023-11-03
|
Bexmarilimab activates human tumor-associated macrophages to support adaptive immune responses in interferon-poor immune microenvironments
published
| article-journal
doi:10.1158/2326-6066.cir-23-0350
|
2023-04-18
|
Bexmarilimab-induced macrophage activation leads to treatment benefit in solid tumors: the phase I/II first-in-human MATINS trial
unknown status
| post
doi:10.1101/2023.04.17.23288693
|
2023-05-12
|
Respiratory Complex I Regulates Dendritic Cell Maturation in Explant Model of Human Tumor Immune Microenvironment
unknown status
| post
doi:10.1101/2023.05.10.539944
|
2024-05-14
|
Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses
unknown status
| post
doi:10.1101/2024.05.11.593502
|
2024-06-03
|
Clinical landscape of macrophage-reprogramming cancer immunotherapies
published
| article-journal
doi:10.1038/s41416-024-02715-6
|
2024-10-27
|
Secreted Clever-1 Modulates T Cell Responses and Impacts Cancer Immunotherapy Efficacy
unknown status
| post
| CC-BY-NC-ND
doi:10.1101/2024.10.23.619796
|
2024-01-03
|
Figure S4 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935451.v1
|
2024-01-03
|
Figure S5 from Bexmarilimab Activates Human Tumor-Associated Macrophages to Support Adaptive Immune Responses in Interferon-Poor Immune Microenvironments
unknown status
| post
| CC-BY
doi:10.1158/2326-6066.24935448
|